Cambridge Healthtech Institute’s 14th Annual

Fragment-Based Drug Discovery
( 基于碎体的新药发现 )

From Hits to Leads and Lessons Learned


Fragment-based drug discovery (FBDD) has proven to be a successful approach for finding new drug compounds, especially against difficult targets such as intracellular protein-protein interactions (PPIs). Quite a few drugs on the market today can trace their origins to hits from fragment-based library screening campaigns. Now that FBDD has been folded into many early drug discovery departments, questions such as how to merge hits arising from fragment-based screens with hits from traditional high throughput screening methods are more frequent. Plus, the challenge of growing fragment hits into drug leads still remains, especially when the fragment and target do not have co-crystal structures to guide ligand design. Discuss these questions and more at Cambridge Healthtech Institute's 14th annual Fragment-Based Drug Design conference, the original FBDD meeting of the industry. We will continue our tradition of providing a forum for leaders and practitioners in the field to learn from one another by sharing success stories and challenges.

Coverage will include, but is not limited to:


  • Fragments for PPIs and other ‘no-pocket’ type targets
  • Advancing from 'fragment hits' to 'lead compounds': linking and growing fragments
  • Innovations in fragment library design
  • New or improved biophysical methods for screening fragment-based libraries
  • Synergizing FBDD campaigns with other drug discovery approaches
  • Optimizing fragment leads without crystal structures
  • Case studies of FBDD origin compounds progressing in development
  • Retrospective stories of FBDD success

* 活动内容有可能不事先告知作更动及调整。